Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $3.9050 (-1.88%) ($3.7900 - $3.9050) on Fri. Feb. 25, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.13% (three month average) | RSI | 40 | Latest Price | $3.9050(-1.88%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -2.4% a day on average for past five trading days. | Weekly Trend | AUTL declines -4.8% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XBI(65%) IBB(61%) IBUY(54%) IWO(53%) XRT(52%) | Factors Impacting AUTL price | AUTL will decline at least -2.065% in a week (0% probabilities). VIXM(-50%) VXX(-27%) TLT(-27%) TIP(-26%) SHY(-25%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.065% (StdDev 4.13%) | Hourly BBV | -0.1 () | Intraday Trend | 0% | | | |
|
Resistance Level | $4.24 | 5 Day Moving Average | $4.02(-2.86%) | 10 Day Moving Average | $4.24(-7.9%) | 20 Day Moving Average | $4.24(-7.9%) | To recent high | -43.2% | To recent low | 5% | Market Cap | $204m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |